The fellowship places Dr. Zaribaf and Invibio at the forefront of a transformative initiative targeting a global concern affecting 1 in 4 adults: cartilage lesions. The ambitious project aims to revolutionize cartilage lesion repair on a global scale. Left untreated, these lesions can lead to severe clinical issues, impacting over 60% of patients undergoing total knee replacement.
In response to this critical issue, Dr. Zaribaf's fellowship will spearhead the development of a groundbreaking technology platform for cartilage lesion repair. Harnessing the proven properties of Invibio's PEEK-OPTIMA™, the project seeks to establish a platform technology for a highly effective treatment option. Addressing the current lack of clinically proven long-term outcomes for cartilage lesion treatments, this innovative project aims to fill that void.
The selection process for the UKRI Future Leaders Fellowships was exceptionally rigorous, with a notoriously low success rate. Dr. Zaribaf's project underwent meticulous evaluation, considering Research & Innovation Excellence, Applicant & their Development, Impact & Strategic Relevance, and Host Organization. This rigorous process, spanning a year, included the submission of a comprehensive project outline, application, and an interview with industry-based senior leaders.
Ian Revie, Head of Horizon 2 Programmes at Invibio comments, "We are incredibly proud of Dr. Zaribaf's accomplishment. At Invibio, our unparalleled expertise propels us forward, and we eagerly champion this pivotal research. Committed to pushing the boundaries of innovation, we hope to leverage our trusted PEEK-OPTIMA™ polymer with the ultimate goal of enhancing patient outcomes."